Case Reports Clinical Chemistry 2023 Exercise 1: Drug-Drug Interaction: Paxlovid (Nirmatrelvir/Ritonavir)–Induced Acute Tacrolimus Toxicity in a Solid Organ Transplant Recipient

Authors

Hsuan-Chieh Liao, PhD, DABCC

University Of Washington

Hema Ketha, PhD, NRCC, SC(ASCP)

LabCorp

Burlington, North Carolina 

Craig Baker BS, C(ASCP)

Pratistha Ranjitkar, PhD, DABCC

LabCorp

Seattle, Washington

Primary Audience: Pathologists and Clinical Scientists
Secondary Audience: Residents, Laboratory Technologist/Scientist (Includes all sub-specialty areas), Students, Pathologist Assistants,  Laboratory Directors and Educators

Upon completion of this activity, you will be able to:

·         describe the use of nirmatrelvir/ritonavir (Paxlovid [Pfizer], formerly known as PF-07321332) in COVID-19 treatment;

·         describe the role of tacrolimus in transplant recipients;

·         explain the metabolism and measurement of tacrolimus;

·         define drug-drug interactions between tacrolimus and Paxlovid; and

·         discuss the use of an enzyme inducer in treating supratherapeutic tacrolimus levels.